Since the results of conventional hematopoietic stem-cell transplantation (HSCT) for patients with dyskeratosis congenita (DC) are poor owing to the high incidence of transplant-related complications, we explored the use of a low-intensity HSCT regimen. We report two children with DC with severe cytopenia, who underwent successful HSCT from a matched unrelated donor after conditioning with fludarabine, cyclophosphamide, and antithymocyte globulin. Graft-versus-host-disease (GVHD) prophylaxis consisted of corticosteroids and cyclosporin A. The regimen was well tolerated, no significant transplantrelated complications were observed, and engraftment was rapid and complete. At 15 and 16 months after HSCT, the children were fully engrafted, in excellent clinical condition, full-donor chimerism, and no signs of GVHD. We conclude that a low-intensity regimen is sufficient to induce durable engraftment using matched unrelated donor HSCT in DC patients, with minimal 1-year transplant-related toxicity. Longer follow-up will determine whether this regimen also reduces long-term toxicity. Bone Marrow Transplantation (2003) 31, 847-850. doi:10.1038/sj.bmt.1703931 Keywords: dyskeratosis congenita; hematopoietic stem cell transplantation; non-myeloablative; congenital aplastic anemia; fludarabine Dyskeratosis congenita (DC) is an inherited multisystem disorder characterized by varying degrees of bone marrow failure, along with other somatic manifestations, and a propensity for myeloid and solid tumors.
cell transplantation; non-myeloablative; congenital aplastic anemia; fludarabine Dyskeratosis congenita (DC) is an inherited multisystem disorder characterized by varying degrees of bone marrow failure, along with other somatic manifestations, and a propensity for myeloid and solid tumors. [1] [2] [3] Bone marrow failure is the principal cause of death, followed by predisposition to malignancy and fatal pulmonary failure. 3 The only cure for patients who develop severe bone marrow complications is hematopoietic stemcell transplantation (HSCT). However, because of the high incidence of early and late complications, results of conventional HSCT for patients with DC are poor. 4 Several recent studies suggested that a low-intensity or nonmyeloablative HSCT regimen incorporating fludarabine might produce a high engraftment rate with low toxicity in both matched related donor HSCT [5] [6] [7] and alternative HSCT (ie from unrelated or one antigenmismatched related donor). [8] [9] [10] We explored the use of such a regimen for two patients with DC, who had severe bone marrow failure. The primary end point was the achievement of durable engraftment; secondary end point was reduced toxicity.
Patients

A 3
1 2 -year-old boy (patient 1) presented with easy bruising. The family medical history was unremarkable. The pregnancy and delivery, and his growth and development were normal. He had had characteristic dystrophic, small fingernails, and toenails with longitudinal ridges, and intermittent buccal and tongue leukoplakia since birth. Laboratory investigation revealed hemoglobin levels of 10.9 g/dl; mean corpuscular volume, 98 fl; platelet count, 19 Â 10 9 /l; neutrophil count, 1.0 Â 10 9 /l; fetal hemoglobin, 9.5%; von Willebrand factor, 1.4 U/ml; normal T, B, and natural killer-cell subpopulations; and normal immunoglobulins G, M, and A. Bone marrow aspirate and biopsy showed severe hypocellularity and normal karyotype. The patient had platelet counts of 8-15 Â 10 9 /l combined with bruising and intermittent rectal bleeding, but was managed with minimal transfusions until transplant.
An 8-year-old girl (patient 2) presented with easy bruising. Her family history was unremarkable. The pregnancy and delivery, and her growth and development were normal. She had had characteristic dystrophic, small fingernails, and toenails with longitudinal ridges for several years, dacryostenosis, and intermittent discoloration of the tongue and buccal mucosa. Laboratory investigations revealed hemoglobin of o7.0 g/dl, platelets o10 Â 10 9 /l, neutrophils o0.5 Â 10 9 /l and erythrocyte mean corpuscular volume of 102 fl. Bone marrow examination showed severe hypocellularity and normal karyotype. She received multiple platelet and red blood cell transfusions (total 420) and daily injections of granulocyte-colony-stimulating factor.
Despite the clear-cut clinical diagnosis, both patients had neither DKC1 or hTR gene mutation (courtesy of Dr I Dokal, London, UK). Mutations in these genes are responsible for the X-linked recessive and autosomal dominant forms of the disease, but not for the autosomal recessive form.
11,12
Methods
Transplant procedure
Conditioning treatment for both patients included fludarabine (30 mg/m 2 /day) from day -10 to day -5, cyclophosphamide (60 mg/kg/day) day -6 and day -5, and equine antithymocyte globulin (ATGAM, Upjohn, Kalamazoo, MI, USA 40 mg/kg/day) from day -4 to day -1. Parents of both patients consented to this conditioning regimen. The protocol was approved by our institutional Research Ethics Board.
The patients received non-T-cell-depleted bone marrow allografts from 6/6 antigen-molecularly-matched unrelated donors. The total number of infused nucleated cells was 5.7 Â 10 8 /kg, and 6.0 Â 10 8 /kg for patients 1 and 2, respectively.
Prophylaxis against graft-versus-host disease (GVHD) consisted of intravenous cyclosporin A twice daily, starting on day -1, with a target serum trough level of 155-210 ng/ ml. When oral caloric intake was fully resumed cyclosporine A was given orally until 3 months after transplant, and was then gradually tapered. In addition, oral prednisone (0.5 mg/kg) twice daily was given starting at day À5 and continued until day +28, then tapered over 14 days. We used prednisone in the GVHD prophylaxis regimen instead of methotrexate to allow concomitant protection from side effects of ATGAM early post transplant.
Supportive care
The patients received granulocytecolony-stimulating factor (5 mg/kg/day) intravenously starting from day +5 until their absolute neutrophil counts were 41.0 Â 10 9 /l for at least two consecutive days. They also received intravenous immunoglobulin (0.5 g/kg) weekly for the first month after the transplant. Intravenous pentamidine (4 mg/kg) was administered every 2 weeks starting at day +14.
Both patients received fluconazole (5 mg/kg/day) orally from day -1 until myeloid engraftment as prophylaxis against fungal infections, and acyclovir (250 mg/m 2 Â 3/day) orally from day -1 until day 28, because of herpes simplex 1 seropositivity. Both patients and donors were serologically negative for cytomegalovirus.
Results
The patients' stay in the hospital was relatively short; 17 and 26 days for patients 1 and 2, respectively. In patient 1, neutrophil counts decreased to 0.3 Â 10 9 /l, and in patient 2, to less than 0.1 Â 10 9 /l. Neutrophil engraftment occurred at day 12 in both cases. Platelet engraftment occurred at days 13 and 14 for patients 1 and 2, respectively. Chimerism studies at 1, 3, and 6 months after HSCT showed 490% donor chimerism with polymerase chain reaction-based analysis of polymorphic microsatellite regions 11 in both cases.
Patient 1 had fever during neutropenia for 1 day, which was treated with piperacillin and tobramycin until neutrophil recovery. Patient 2 had fever during neutropenia without detection of microorganisms for 6 days. Her fever was treated with piperacillin and tobramycin until neutrophil engraftment. She had Epstein-Barr virus reactivation 2 months after the transplant, which was treated successfully with ganciclovir and cytomegalovirus hyperimmune globulin.
Neither patient experienced mucositis, and only patient 2 required total parenteral nutrition for a week. No signs of GVHD appeared in either patient.
At 15 and 16 months after HSCT, the children were in excellent clinical condition, transfusion independent, with full-donor chimerism and receiving no immunosuppression. Both patients had normal hemoglobin and neutrophil counts. Patient 2 had platelet counts 4200 Â 10 9 /l. Patient 1 had platelet counts of 90-120 Â 10 9 /l. At 13 months post HSCT bone marrow aspirate revealed a normocellular specimen with active trilineage hematopoiesis, no dysplasia and normal cytogenetics. At this stage he had 490% donor chimerism of peripheral blood lymphocytes and marrow mononuclear cells.
Discussion
These cases demonstrate for the first time that low-intensity HSCT using an HLA-matched unrelated donor can be safely and effectively used for patients with DC. Although graft rejection is a major concern in an alternative-HSCT setting, recent results of a small series have shown that durable and stable engraftment can be achieved with a lowintensity conditioning regimen to prepare for the transplantation of matched unrelated bone marrow allografts. 8, 9 From the present cases, it seems that low-intensity conditioning may also be safely applied to patients with DC in need of a bone marrow transplant from an HLAmatched unrelated donor and that durable trilineage engraftment may result. Further, it seems that this approach may also be associated with reduced transplantrelated toxicity when applied to patients with DC. Organ toxicity and side effects were mild and substantially less than the published figures in DC, 3, 4 and for alternative HSCT after conventional myeloablative conditioning in other disorders. 14, 15 To date, 22 patients with DC have undergone HSCT (Table 1) . Only four cases were from a MUD, and standard conditioning regimens were used in most cases. [2] [3] [4] [16] [17] [18] [19] [20] [21] [22] [23] [24] No HSCT regimens incorporating fludarabine have been utilized in DC thus far. Of these patients, only 10 survived longer than 3 years after HSCT, and among the survivors there is only one who was transplanted from a MUD. 3, [20] [21] [22] [23] Short-term transplant-related toxicity is common in this population and causes include sepsis, GVHD, and early
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Y Dror et al death. 22, 24, 25 Vascular lesions and fibrosis involving various organs can occur in DC patients in both the early and late periods after transplantation and carry a high mortality rate. These patients may be more susceptible to endothelial damage, 3, 26 which occurs after HSCT as a result of various factors, including the conditioning regimen, cyclosporin A, infectious diseases, GVHD, and cytokine storm. 27 Another striking complication for patients with DC after HSCT is bronchopulmonary disease. An inherent propensity for pulmonary disease 28 may explain the high incidence (up to 40%) of early and late fatal pulmonary complications after HSCT. 3, 4, 16, 17, 22, 25 The unusual complications uniquely seen in DC have not been reported in other inherited bone-marrow-failure syndromes such as Fanconi's anemia. 4, 29 DC is a disorder involving a subtle degree of chromosomal instability with a predisposition to chromosomal rearrangements, 30 rather than to gaps and breaks as seen in Fanconi's anemia. The recent published defects in telomerase and telomere shortening shed additional light on the hypersensitivity to irradiation and chemotherapy found in patients with this disorder. 11, 12 Therefore, the increased hypersensitivity of DC patients to transplant conditioning can be related to the inherent extreme telomere shortening 31 combined with the accelerated telomere shortening occurring after HSCT. 32 The increased predisposition to post-transplant complications, especially pulmonary and vascular, the chromosomal instability and the tendency to develop tumors highlight the need to avoid certain conditioning agents such as busulfan and irradiation. Reports 33, 34 of a fludarabine-based regimen for HSCT in patients with Fanconi's anemia have recently been published. No studies have yet been carried out on the in vitro or in vivo effect of fludarabine on the primary defects found in patients with DC. However, from what is known about the mechanism of action of fludarabine, there is no reason to believe that it will be more toxic than irradiation to abnormal telomerase activity and telomere shortening in patients with DC.
We demonstrated durable engraftment with reduced transplant-related toxicity using low-intensity conditioning in DC. This is of the utmost importance for patients with DC and other similar inherited bone-marrow-failure syndromes who need HSCT, but whose basic genetic disorder causes them to be more susceptible to transplant-related toxicity. Longer follow-up is still needed to clarify whether long-term toxicity is also reduced by such a regimen. ATG, antithymocytic globulin; Bus, busulfan in mg/m 2 ; CMV, cytomegalovirus; Cy, cyclophosphamide in mg/kg; F, female; M, male; GVHD, graft-versushost disease, MRD, matched-related donor; MUD, matched-unrelated donor; NM, not mentioned; *cause of death; TAI, thorocoabdominal irradiation in Gy; TBI, total body irradiation in Gy; TTP, thrombotic thrombocytopenia purpura.
